ReadYourDNA

Escitalopram (Lexapro)

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Escitalopram

What it is

Escitalopram is an antidepressant of the SSRI group: it keeps more of the messenger serotonin available between nerve cells. It is the active half of citalopram, the mirror-image form that does the work. It is used for depression and generalised anxiety, and in some countries for panic disorder, social anxiety and obsessive-compulsive disorder. It is sold as Lexapro and Cipralex, among other names.

How genes come into it

Escitalopram is broken down mainly by the liver enzyme CYP2C19. People with two low-function copies (poor metabolizers) have clearly higher blood levels, and people with the fast *17 version on both copies (ultrarapid metabolizers) have lower ones. CPIC and DPWG have published guidelines on CYP2C19 and escitalopram, and the US FDA lists an effect on drug levels. Studies have also looked at the transporter ABCB1, serotonin genes such as HTR2A and SLC6A4, and CYP2D6, with weaker evidence.

Published guidelines

Clinical guidelines that name a gene for Escitalopram. They sort people into groups by the gene copies they carry.

CPIC guideline: CYP2C19. Ultrarapid Metabolizer · Rapid Metabolizer · Normal Metabolizer · Likely Intermediate Metabolizer · Intermediate Metabolizer · Likely Poor Metabolizer · Poor Metabolizer · Indeterminate. Strong. 2023.

DPWG guideline: CYP2C19. Ultrarapid Metabolizer · Rapid Metabolizer · Normal Metabolizer · Likely Intermediate Metabolizer · Intermediate Metabolizer · Likely Poor Metabolizer · Poor Metabolizer · Indeterminate. 2022.

US FDA: CYP2C19. Ultrarapid Metabolizer · Likely Intermediate Metabolizer · Intermediate Metabolizer · Likely Poor Metabolizer · Poor Metabolizer. Data that Demonstrate a Potential Impact on Pharmacokinetic Properties Only.

What research found

Every published finding on gene variants and Escitalopram. Upload your DNA file to see which of these rows apply to you.

Rated evidence (27 rated variants)

PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.

CYP2C19 CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17: Level 1A · replicated. Metabolism/PK: Major Depressive Disorder, Mental Disorders. 11.

HTR2A rs6311: Level 3. Toxicity: Anxiety Disorders, Major Depressive Disorder. 6.

CYP1A2 rs2069526: Level 3. Toxicity: Major Depressive Disorder. 1.

HTR2A rs9316233: Level 3. Efficacy: Depressive Disorder. 1.

Metabolism (41 findings)

Studies of how quickly the body processes this medication.

rs2069521: Allele A is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele G.

CYP1A2 rs2069526: Allele G is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele T.

CYP1A2 rs4646425: Allele T is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele C.

CYP1A2 rs4646427: Allele C is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele T.

Response (68 findings)

Studies of how well it worked in people carrying a variant.

rs12154537: Allele G is associated with increased response to escitalopram in people with Depressive Disorder, Major as compared to allele A.

BDNF rs6265: Genotype CC is associated with increased clinical benefit to citalopram, escitalopram, fluoxetine or sertraline in people with Major Depressive Disorder as compared to genotypes CT + TT.

BDNF rs6265: Genotype CC is associated with increased clinical benefit to escitalopram, fluoxetine, paroxetine or sertraline in people with Major Depressive Disorder as compared to genotypes CT + TT.

BDNF rs6265: Genotype CC is associated with increased clinical benefit to citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Major Depressive Disorder as compared to genotypes CT + TT.

Dosing (2 findings)

Studies of how much of the drug people needed or tolerated.

CYP2D6 CYP2D6*1, CYP2D6*4: CYP2D6 *4/*4 is associated with decreased dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Depression as compared to CYP2D6 *1/*1.

CYP2C19 CYP2C19*1, CYP2C19*2: CYP2C19 *1/*2 + *2/*2 are not associated with dose of escitalopram in people with Autistic Disorder as compared to CYP2C19 *1/*1.

Side effects (2 findings)

Studies of side effects in people carrying a variant.

CYP2C19 CYP2C19*1, CYP2C19*17: CYP2C19 *1/*17 + *17/*17 (assigned as ultrarapid metabolizer phenotype) are not associated with response to citalopram, escitalopram or sertraline in women with Depression and Pregnancy as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .

CYP2C19 CYP2C19*1, CYP2C19*2, CYP2C19*17: CYP2C19 *1/*2 + *2/*17 + *2/*2 (assigned as intermediate metabolizer and poor metabolizer phenotype) are not associated with response to citalopram, escitalopram or sertraline in women with Depression and Pregnancy as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Celexa (SSRIs)

Luvox (SSRIs)

Paxil (SSRIs)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com